OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka
Chandima Jeewandara, Inoka Sepali Aberathna, Saubhagya Danasekara, et al.
Immunology (2022) Vol. 167, Iss. 2, pp. 263-274
Open Access | Times Cited: 14
Chandima Jeewandara, Inoka Sepali Aberathna, Saubhagya Danasekara, et al.
Immunology (2022) Vol. 167, Iss. 2, pp. 263-274
Open Access | Times Cited: 14
Showing 14 citing articles:
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Dominique J. Barbeau, Judith M. Martin, Emily Carney, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 27
Dominique J. Barbeau, Judith M. Martin, Emily Carney, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 27
Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
Protim Sarker, Evana Akhtar, Rakib Ullah Kuddusi, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1498-1498
Open Access | Times Cited: 15
Protim Sarker, Evana Akhtar, Rakib Ullah Kuddusi, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1498-1498
Open Access | Times Cited: 15
Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
Pradeep Darshana Pushpakumara, Chandima Jeewandara, Farha Bary, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Pradeep Darshana Pushpakumara, Chandima Jeewandara, Farha Bary, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study
И. О. Стома, K. S. Korsak, Е. В. Воропаев, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21877-e21877
Open Access | Times Cited: 4
И. О. Стома, K. S. Korsak, Е. В. Воропаев, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21877-e21877
Open Access | Times Cited: 4
Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals
Pradeep Darshana Pushpakumara, Chandima Jeewandara, Farha Bary, et al.
Clinical & Experimental Immunology (2023) Vol. 215, Iss. 3, pp. 268-278
Open Access | Times Cited: 4
Pradeep Darshana Pushpakumara, Chandima Jeewandara, Farha Bary, et al.
Clinical & Experimental Immunology (2023) Vol. 215, Iss. 3, pp. 268-278
Open Access | Times Cited: 4
Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases
Vikas Gupta, Vikram Kumar Gupta, Navjot Bajwa, et al.
Journal of Family Medicine and Primary Care (2024) Vol. 13, Iss. 5, pp. 1904-1910
Open Access | Times Cited: 1
Vikas Gupta, Vikram Kumar Gupta, Navjot Bajwa, et al.
Journal of Family Medicine and Primary Care (2024) Vol. 13, Iss. 5, pp. 1904-1910
Open Access | Times Cited: 1
Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
Chandima Jeewandara, Inoka Sepali Aberathna, Shashika Dayarathna, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0274845-e0274845
Open Access | Times Cited: 5
Chandima Jeewandara, Inoka Sepali Aberathna, Shashika Dayarathna, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0274845-e0274845
Open Access | Times Cited: 5
Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
Chandima Jeewandara, K. A. Chintha S. Jayampathi, Thushali Ranasinghe, et al.
PLOS Global Public Health (2022) Vol. 2, Iss. 7, pp. e0000607-e0000607
Open Access | Times Cited: 4
Chandima Jeewandara, K. A. Chintha S. Jayampathi, Thushali Ranasinghe, et al.
PLOS Global Public Health (2022) Vol. 2, Iss. 7, pp. e0000607-e0000607
Open Access | Times Cited: 4
Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
Bothamai Dechates, Thachanun Porntharukchareon, Supamas Sirisreetreerux, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 684-684
Open Access | Times Cited: 1
Bothamai Dechates, Thachanun Porntharukchareon, Supamas Sirisreetreerux, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 684-684
Open Access | Times Cited: 1
RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia
Burenjargal Batmunkh, Otgonbayar Dashpagma, Shatar Shaarii, et al.
PLoS ONE (2023) Vol. 18, Iss. 12, pp. e0295167-e0295167
Open Access | Times Cited: 1
Burenjargal Batmunkh, Otgonbayar Dashpagma, Shatar Shaarii, et al.
PLoS ONE (2023) Vol. 18, Iss. 12, pp. e0295167-e0295167
Open Access | Times Cited: 1
Evaluation of the Diagnostic Performance of Two Automated SARS-CoV-2 Neutralization Immunoassays following Two Doses of mRNA, Adenoviral Vector, and Inactivated Whole-Virus Vaccinations in COVID-19 Naïve Subjects
Eszter Csoma, Ágnes Nagy Koroknai, Renáta Sütő, et al.
Microorganisms (2023) Vol. 11, Iss. 5, pp. 1187-1187
Open Access
Eszter Csoma, Ágnes Nagy Koroknai, Renáta Sütő, et al.
Microorganisms (2023) Vol. 11, Iss. 5, pp. 1187-1187
Open Access
Challenges of conducting an international observational study to assess immunogenicity of multiple COVID-19 vaccines
Ratna Sardana, Placide Mbala Kingebeni, Wiwit Agung SNC, et al.
PLOS Global Public Health (2023) Vol. 3, Iss. 6, pp. e0001918-e0001918
Open Access
Ratna Sardana, Placide Mbala Kingebeni, Wiwit Agung SNC, et al.
PLOS Global Public Health (2023) Vol. 3, Iss. 6, pp. e0001918-e0001918
Open Access
Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine
Romanee Chaiwarith, Poramed Winichakoon, Parichat Salee, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access
Romanee Chaiwarith, Poramed Winichakoon, Parichat Salee, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access
